SL44
SL44 is an agonist for human caseinolytic protease P (HsClpP), with an EC50 of 1.30 μM. SL44 inhibits the proliferation of LM3 with an IC50 of 3.1 μM. SL44 induces apoptosis in HCC cells, through the degradation of respiratory chain complex subunits. SL44 exhibits antitumor efficacy in mouse models without obvious toxicity (LD50=400 mg/kg) . SL44 exhibits good pharmacokinetic characters in rat models[1].
Product Specifications
UNSPSC
12352005
Target
ClpP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sl44.html
Purity
99.57
Solubility
DMSO : 70 mg/mL (ultrasonic)
Smiles
ClC1=C(F)C=CC(CC2=NOC(C3CCN(CC4=CC=CC(C#N)=C4)CC3)=N2)=C1
Molecular Formula
C22H20ClFN4O
Molecular Weight
410.87
References & Citations
[1]Gao Y, et al., Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment. J Med Chem. 2024 Jun 24.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Browse additional items from our catalog
